Archive


Category: EYLEA

  • Oxurion reports stronger data for diabetic eye disease drug

    Belgian biotech Oxurion has revealed new data from a phase 2 trial of its plasma kallikrein inhibitor THR-149, in development for people with diabetic macular oedema (DME) who don’t respond to standard therapy. New results from the first of two stages in the KALAHARI study of THR-149 showed that patients treated with the drug had […]

  • Roche grabs FDA okay for would-be blockbuster eye drug faricimab

    The FDA has approved Roche’s much-anticipated faricimab for two major causes of blindness, setting up a market clash with Bayer and Regeneron’s market leading drug Eylea. The US regulator has given the green light to the bispecific antibody – now called Vabysmo – for both neovascular or ‘wet’ age-related macular degeneration (AMD) and diabetic macular […]

  • FDA clears Roche’s Susvimo implant for eye disease wet AMD

    Roche’s Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration (AMD) that gives patients an alternative to regular injections into the eye. Susvimo has the same active ingredient as Roche’s big-selling therapy Lucentis (ranibizumab), a VEGF inhibitor administered once a month that has been approved by the […]

  • Novartis says trials back Beovu safety in diabetic eye disease

    There is plenty of evidence that Novartis’ ophthalmology drug Beovu can match its rivals when it comes to efficacy, with less frequent dosing, but the big question facing the company is whether it is less safe. Data from phase 3 trials of the drug in diabetic macular oedema (DMO) provide some encouragement for Novartis on […]

  • Novartis says trials back Beovu safety in diabetic eye disease

    There is plenty of evidence that Novartis’ ophthalmology drug Beovu can match its rivals when it comes to efficacy, with less frequent dosing, but the big question facing the company is whether it is less safe. Data from phase 3 trials of the drug in diabetic macular oedema (DMO) provide some encouragement for Novartis on […]

  • FDA starts review of Roche’s eye disease drug, setting up 2022 verdict

    The FDA has started a priority review of Roche’s bispecific antibody faricimab for two major causes of blindness, preparing for a market showdown with Bayer and Regeneron’s market-leading Eylea. The US regulator will review the drug for both neovascular or ‘wet’ age-related macular degeneration (AMD) and diabetic macular oedema (DME), as well as diabetic retinopathy […]

  • Novartis halts three trials of Beovu eye drug on safety concerns

    Prospects for Novartis’ ophthalmology drug Beovu have taken another dive after the drugmaker reported toxicity issues in a new phase 3 trial in wet age-related macular degeneration (AMD). On the plus side, Beovu (brolucizumab) met its efficacy objectives in the MERLIN study, but that was offset by higher rates of inflammatory reactions in the eyes […]

  • Bayer slides on €9.5bn loss caused by litigation, COVID-19 impact

    Bayer counted the cost of its expensive Roundup weedkiller settlement in the second quarter with a €9.5 billion net loss made worse by lower sales in its pharma and consumer health divisions. Group sales were down 2.5% to just over €10 billion, with pharma falling 8.8% to just under €4 billion, “weighed down” by COVID-19 […]

  • Top 20 Prescription Drugs Based on 2019 Revenue

    The average life expectancy span of Human Beings are increased due to better medical facilities and drugs developed by Biopharma companies. Pharmaceutical products or drugs or medicines are being produced for a wide range of medical sectors. It includes the lifesaving drugs or the major therapy area including immunology, cardiology, and neurology but are they […]